Millipore Sigma Vibrant Logo

422000 Kenpaullone - CAS 142273-20-9 - Calbiochem

A potent, cell-permeable, and reversible inhibitor of glycogen synthase kinase-3β (IC₅₀ = 230 nM), Lck (IC₅₀ = 470 nM), and cyclin-dependent kinases (Cdks).

Kenpaullone - CAS 142273-20-9 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: 9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one, NSC-664704

Primary Target: Gsk-3β
View Products on Sigmaaldrich.com
422000
View Pricing & Availability

Overview

Replacement Information

Key Spec Table

CAS #Empirical Formula
142273-20-9C₁₆H₁₁BrN₂O

Pricing & Availability

Catalogue Number AvailabilityPackaging Qty/Pack Price Quantity
422000-1MG
Retrieving availability...
—
Limited Availability Limited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      		 Ampul plastik 1 mg
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity is a multiple of
      Maximum Quantity is
      Upon Order Completion More Information
      You Saved ()
       
      —
      Request Pricing
      		 —
      Description
      OverviewA potent, cell-permeable, and reversible inhibitor of glycogen synthase kinase-3β (IC50 = 230 nM), Lck (IC50 = 470 nM), and cyclin-dependent kinases (Cdks). Inhibits Cdk1/cyclin B (IC50 = 400 nM), Cdk2/cyclin A (IC50 = 680 nM), Cdk2/cyclin E (IC50 = 7.5 µM), and Cdk5/p25 (IC50 = 850 nM). Also inhibits other kinases such as c-Src (IC50 = 15 µM), casein kinase II (IC50 = 20 µM), ERK1 (IC50 = 20 µM), and ERK2 (IC50 = 9 µM). Inhibition is competitive with respect to ATP binding.
      Catalogue Number422000
      Brand Family Calbiochem®
      Synonyms9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one, NSC-664704
      References
      ReferencesBain, J., et al. 2003. Biochem. J. 371, 199.
      Buolamwini, J.K. 2000. Curr. Pharm. Des. 6, 379.
      Schultz, C., et al. 1999. J. Med. Chem. 42, 2909.
      Zaharevitz, D.W., et al. 1999. Cancer Res. 59, 2566.
      Product Information
      CAS number142273-20-9
      ATP CompetitiveY
      FormYellow-brown solid
      Hill FormulaC₁₆H₁₁BrN₂O
      Chemical formulaC₁₆H₁₁BrN₂O
      ReversibleY
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetGsk-3β
      Primary Target IC<sub>50</sub>230 nM, 470 nM, 400 nM, 680 nM, 7.5 µM, 850 nM, 15 µM, 20 µM, 20 µM, 9 µM against glycogen synthase kinase-3β, Lck IC50, Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, and Cdk5/p25, c-Src, casein kinase II, ERK1, and ERK2
      Purity≥95% by HPLC
      Physicochemical Information
      Cell permeableY
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Catalogue Number GTIN
      422000-1MG 04055977187137

      Documentation

      Kenpaullone - CAS 142273-20-9 - Calbiochem MSDS

      Title

      Safety Data Sheet (SDS) 

      Kenpaullone - CAS 142273-20-9 - Calbiochem Certificates of Analysis

      TitleLot Number
      422000

      References

      Reference overview
      Bain, J., et al. 2003. Biochem. J. 371, 199.
      Buolamwini, J.K. 2000. Curr. Pharm. Des. 6, 379.
      Schultz, C., et al. 1999. J. Med. Chem. 42, 2909.
      Zaharevitz, D.W., et al. 1999. Cancer Res. 59, 2566.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision30-December-2009 RFH
      Synonyms9-Bromo-7,12-dihydroindolo[3,2-d][1]benzazepin-6(5H)-one, NSC-664704
      DescriptionA potent cell-permeable and reversible inhibitor of glycogen synthase kinase-3β (IC50 = 230 nM), Lck (IC50 = 470 nM), and cyclin-dependent kinases (Cdks). Inhibits Cdk1/cyclin B (IC50 = 400 nM), Cdk2/cyclin A (IC50 = 680 nM), Cdk2/cyclin E (IC50 = 7.5 µM), and Cdk5/p25 (IC50 = 850 nM). Also inhibits other kinases such as c-Src (IC50 = 15 µM), casein kinase II (IC50 = 20 µM), ERK1 (IC50 = 20 µM), and ERK2 (IC50 = 9 µM). Inhibition is competitive with respect to ATP binding.
      FormYellow-brown solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number142273-20-9
      Chemical formulaC₁₆H₁₁BrN₂O
      Structure formulaStructure formula
      Purity≥95% by HPLC
      SolubilityDMSO (100 mg/ml)
      Storage Protect from light
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesBain, J., et al. 2003. Biochem. J. 371, 199.
      Buolamwini, J.K. 2000. Curr. Pharm. Des. 6, 379.
      Schultz, C., et al. 1999. J. Med. Chem. 42, 2909.
      Zaharevitz, D.W., et al. 1999. Cancer Res. 59, 2566.